BioAtla, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BCAB | ATORX.ST | BOLT | PPBT | APVO | IMMP | |
|---|---|---|---|---|---|---|
| Market cap | 3.34M | 38.54M | 15.42M | 1.98M | 2.90M | 21.74M |
| P/E (TTM) | — | — | — | — | 0.0 | — |
| Forward P/E | -1.5 | -0.1 | -0.3 | -1.2 | -0.1 | -0.9 |
| Price/book | -0.1 | 0.3 | 1.0 | 0.1 | 0.3 | 0.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −93.75% | −99.41% | +34.91% | −85.52% | −94.72% | −91.38% |
| Today | +6.95% | +0.93% | −0.46% | +2.97% | +0.74% | −1.50% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BCAB news ›BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the…
BioAtla Secures $40 Million Standby Equity Purchase Facility With Yorkville for 36 Months
TradingView BioAtla Secures $40 Million Standby Equity Purchase Facility With Yorkville for 36 Months BioAtla entered a new $40 million Standby Equity Purchase Agreement with Yorkville, providing optional equi
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) ... Context announces buyout of CT-202…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.financialcontent.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.